PE Deals

HIG Capital-backed Aspire Pharma picks up Morningside

The combination will create one of the largest and fastest growing UK pharma companies, according to Aspire CEO Richard Condon.

-
  • Morningside focuses on developing and licensing high volume and niche generic pharmaceutical products
  • HIG acquired Aspire Pharma in September 2021
  • Aspire is a provider of niche generic and branded specialty pharmaceuticals

HIG Capital portfolio company Aspire Pharma announced on Monday that it has acquired Morningside Healthcare and Morningside Pharmaceuticals, together referred to as Morningside. The company, based in Loughborough, England, is a provider of high volume and niche generic and branded speciality pharmaceuticals. The acquisition is set to support further M&A and international expansion.

“A combined Aspire and Morningside bring greater scale, breadth and diversity across products, geographies, and sales channels,” said Rohin Jain, managing director of HIG European middle market and head of healthcare in Europe.

“The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally,” said Richard Condon, CEO of Aspire.

Aspire Pharma, itself a provider of niche generic and branded specialty pharmaceuticals, was acquired by HIG Capital in September 2021. The company is headquartered in Petersfield, England.

Miami-headquartered HIG Capital is a global investor with over $49 billion in assets under management.